BIT Pharma a specialty pharmaceutical company focused on the development of novel products with delivery to the central nervous system and in particular the brain, today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to NicaPlant®  (nicardipine) for the treatment of non-traumatic subarachnoid haemorrhage, a serious, debilitating rare disorder that affects […]

BIT Pharma a specialty pharmaceutical company focused on the development of novel products with delivery to the central nervous system and in particular the brain, today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to NicaPlant®  (nicardipine) for the treatment of non-traumatic subarachnoid haemorrhage, a serious, debilitating rare disorder that affects approximately 1 in 10,000 people in Europe, and worldwide.

 

Contact Us

Send us an email for further inquiry.

Not readable? Change text.